• In late July and early August 2026, Oracle Corporation and its partners announced a series of deals, including an expanded collaboration with Google Cloud to bring Gemini AI models into Oracle’s enterprise applications and new Oracle Health and Oracle Fusion HCM projects with Baycrest Hospital and CACI International for major public-sector modernization efforts.
• Together, these agreements highlight how Oracle is embedding external AI models and its own cloud software into large, long-duration government and healthcare workflows, potentially reinforcing the stickiness and scale of its enterprise platforms.
• We’ll now examine how integrating Google’s Gemini models into Oracle’s Fusion Applications could influence the company’s AI-led investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Oracle Investment Narrative Recap

To own Oracle today, you need to believe its massive AI and cloud bets can convert a record backlog into durable, profitable growth faster than its legacy software declines. The latest Google Gemini and public‑sector modernization deals reinforce the near term catalyst around AI infused Fusion Applications, but they do little to reduce the key risk that Oracle’s heavy AI and data center CapEx could outpace actual workload ramp.

The expanded partnership with Google Cloud to bring Gemini into Oracle Fusion and NetSuite looks most relevant here, because it directly ties AI infrastructure spending to visible, product level use cases. If Gemini powered agents in Fusion meaningfully boost customer adoption and stickiness, that could support the bullish revenue and earnings targets analysts have set, but it also raises the stakes if AI utilization or enterprise budgets fall short.

Yet behind the AI opportunity, investors should also be aware that Oracle’s very high projected CapEx could become a drag if customer demand...

Oracle's narrative projects $181.8 billion revenue and $41.7 billion earnings by 2029. This requires 39.2% yearly revenue growth and an earnings increase of about $24.7 billion from $17.0 billion today.

Uncover how Oracle's forecasts yield a $248.15 fair value, a 69% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already projecting revenue near US$196.6 billion by 2029, so if you believe Oracle’s AI infrastructure buildout and Gemini powered applications will convert quickly, your view is much closer to that bullish camp than the more cautious consensus that worries about underutilized data centers and licensing pressure.

Explore 29 other fair value estimates on Oracle - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oracle research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Oracle research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oracle's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.